Home » Newsletters » BioWorld Science

BioWorld Science

April 21, 2021

View Archived Issues

Sinocelltech starts phase II/III development of SCTA-01 in COVID-19

First patient infused in phase I study of CD19 RPM CAR-T cell therapy

Krystal Biotech provides development updates for KB-407 and KB-408

Revolution Medicines targets SOS-1 with new compound RMC-0331 for RAS-driven cancers

Baricitinib improves hair regrowth in patients with alopecia areata in second BRAVE-AA trial

FDA places clinical hold on proposed phase II study of KVD-824

Positive interim data presented from phase I portion of the AUGMENT-101 study of SNDX-5613

FDA allows Vincerx Pharma to conduct phase Ib study of VIP-152 in CLL and Richter syndrome

Phase II study application for FB-704A in severe asthma receives approval in Taiwan

ECM2 mutation as a biomarker of response to ICIs in patients with melanoma

Discovery and preclinical characterization of novel KRAS G12C inhibitor, LY-3537982

SEP-363856 is associated with robust improvement in negative symptoms of schizophrenia

Sumitomo Dainippon Pharma patents new compounds for cancer

Fujifilm divulges FGFR inhibitors

New GTPase KRAS mutant inhibitors presented by BeiGene

Pivotal study evaluates ION-373 for Alexander disease

Medshine Discovery patent describes LSD1 inhibitors

King's College London presents adeno-associated viral vectors

Novel STING agonists for antitumor immunotherapy

New molecular imaging and therapy trials open at Hoag

FDA clears IND for phase I trial of Transcenta's bifunctional PD-L1/TGF-beta antibody TST-005

AZD-8853, a new anti-GDF15 antibody for cancer immunotherapy

Initiation of NOBLE Registry for Telix's TLX599-CDx SPECT in prostate cancer

CL-2020 studied for ARDS related to COVID-19 in Japan

Trevena's TRV-027 to be studied in REMAP-CAP study for COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
Research grants support early clinical trials of ALS treatments
BioWorld Science
The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...